Acadia Pharmaceuticals (ACAD) said Tuesday it submitted a marketing authorization application to the European Medicines Agency for trofinetide to treat Rett syndrome in patients two years old and older.
Trofinetide is already approved in the US and Canada for Rett syndrome, a neurodevelopmental disorder, the company said.
Separately, Acadia Pharmaceuticals said it expects full-year 2025 net sales to top $1 billion for the first time in company history.
The company's shares were down 4.9% in recent trading.
Price: 17.03, Change: -0.87, Percent Change: -4.86
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.